Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 8/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16502957 | 0.81 | PDE4D (0.39) | NMT1LMNAHTTSMN1; SMN2KDM4E | |
| SCHEMBL18904084 | 0.74 | MAPT (0.48) | LMNAHTTSMN1; SMN2KDM4EMAPT | |
| SCHEMBL18904173 | 0.73 | NMT1 (0.55) | NMT1 | |
| SCHEMBL8281840 | 0.72 | ALDH1A1 (0.40) | SMN1; SMN2L3MBTL1MAPK1 | |
| SCHEMBL18904149 | 0.71 | CYP11B2 (0.38) | NMT1LMNAHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL18903920 | 0.71 | MAPT (0.39) | NMT1LMNAHTTL3MBTL1MAPT | |
| SCHEMBL18904081 | 0.71 | MAPT (0.41) | NMT1LMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL18903785 | 0.70 | LMNA (0.37) | NMT1LMNAHTTSMN1; SMN2KDM4E | |
| SCHEMBL18903996 | 0.69 | NMT1 (0.51) | NMT1 | |
| SCHEMBL16502949 | 0.69 | NMT1 (0.60) | NMT1LMNAHTTSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2980076-B1 | Pyrazolyl derivatives | UNIV DUNDEE (GB) | 2017-05-31 | — | — | EP | disclosed |